< em > FGFR < /em > Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)

CONCLUSIONS: Over 23% of FGFR2/3 fusions in aNSCLC may be associated with acquired resistance following treatment with EGFR TKIs. In this clinical scenario, a combination of EGFR TKIs and FGFR TKIs represents a promising treatment strategy.PMID:35566609 | PMC:PMC9102087 | DOI:10.3390/jcm11092475

Source: Clinical Lung Cancer - May 14, 2022 Category: Cancer & Oncology Authors: Ari Raphael Elizabeth Dudnik Dov Hershkovitz Suyog Jain Steve Olsen Lior Soussan-Gutman Taly Ben-Shitrit Addie Dvir Hovav Nechushtan Nir Peled Amir Onn Abed Agbarya None On Behalf Of The Israel Lung Cancer Group Source Type: research